Addressing Preclinical Gaps to Prevent Biotech Trial Delays
Gain insight into why early toxicology readiness and strong scientific collaboration with CRO partners are critical to accelerating trial startup and regulatory approval.
In a recent video interview with Applied Clinical Trials, Ben Edwards, chief operating officer, Avance Clinical, discussed common challenges in biotech, emphasizing the importance of addressing preclinical package gaps to avoid delays.
He highlighted the need for CROs with deep scientific capabilities to create a sound scientific argument for new drugs.
Edwards also noted the shift towards adaptive trial designs and the benefits of staying with the same CRO for continuity. Effective coordination across functions requires integrated teams and data visualization.
Author's summary: Address preclinical gaps to accelerate biotech trials.
More News
- Who knew that the public would end up supporting striking teachers? Not Danielle Smith and the UCP! - Alberta Politics
- Electric Island Expands with Five Shows and a Massive Lineup
- Who won fashion month SS26 on social media?
- Mateusz Gamrot Releases His First Statement Following His Loss To Charles Oliveira
- Bangladesh inking deals with foreign companies to operate three ports
- Marshalltown Ansons team made city a ‘Baseball Town’
- Wilson is wrong about women’s rights and the 19th Amendment
- From Rails to Trails
- Solomon Named Big South Preseason Player of the Year; Bulldogs Picked Second in Preseason